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Abstract Pituitary adenylate cyclase activating polypeptide (PACAP) is an endogenous 
neuropeptide with a widespread distribution both in the nervous system 
and peripheral organs. The peptide is also present in the female gonadal 
system, indicating its role in reproductive functions. While a lot of data are 
known on PACAP- induced effects in oogenesis and in the regulation of 
gonadotropin secretion at pituitary level, its placental effects are somewhat 
neglected in spite of the documented implantation deficit in mice lacking 
endogenous PACAP. The aim of the present review is to give a brief summary 
on the occurrence and actions of PACAP and its receptors in the placenta. 
Radioimmunoassay (RIA) measurements revealed increased serum PACAP 
levels during the third trimester and several changes in placental PACAP 
content in obstetrical pathological conditions, further supporting the function 
of PACAP during pregnancy.
Both the peptide and its receptors have been shown in different parts of the 
 placenta and the umbilical cord. PACAP influences blood vessel and smooth 
muscle contractility of the uteroplacental unit and is involved in regulation 
of local hormone secretion. The effects of PACAP on trophoblast cells have 
been mainly studied in vitro. Effects of PACAP on cell survival, angiogenesis 
and invasion/proliferation have been described in different trophoblast cell 
lines. PACAP increases proliferation and decreases invasion in proliferative 
extravillous  trophoblast cells, but not in primary trophoblast cells, where PACAP 
decreased the secretion of various angiogenic markers. PACAP pretreatment 
enhances survival of non-tumorous primary trophoblast cells exposed to 
oxidative stress, but it does not influence the cell death-inducing effects of 
methotrexate in proliferative extravillous cytotrophoblast cells. Interestingly, 
PACAP has pro-apoptotic effect in choriocarcinoma cells suggesting that the 
effect of PACAP depends on the type of trophoblast cells. These data strongly 
support that PACAP plays a role in normal and pathological pregnancies and 
our review provides an overview of currently available experimental data 
worth to be further investigated to elucidate the exact role of this peptide in 
the placenta.
Keywords (separated 
by “ - ”)
Pregnancy - Trophoblast - Proliferation - Migration - Placenta - Human
389© Springer International Publishing Switzerland 2016 
D. Reglodi, A. Tamas (eds.), Pituitary Adenylate Cyclase Activating  
Polypeptide — PACAP, Current Topics in Neurotoxicity 11, 
DOI 10.1007/978-3-319-35135-3_23
Chapter 23
Occurrence and Functions of PACAP 
in the Placenta
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Miklos Koppan, Andrea Tamas, Laszlo Szereday, and Dora Reglodi
Abstract Pituitary adenylate cyclase activating polypeptide (PACAP) is an 
endogenous neuropeptide with a widespread distribution both in the nervous sys-
tem and peripheral organs. The peptide is also present in the female gonadal sys-
tem, indicating its role in reproductive functions. While a lot of data are known on 
PACAP- induced effects in oogenesis and in the regulation of gonadotropin secre-
tion at pituitary level, its placental effects are somewhat neglected in spite of the 
documented implantation deficit in mice lacking endogenous PACAP. The aim of 
the present review is to give a brief summary on the occurrence and actions of 
PACAP and its receptors in the placenta. Radioimmunoassay (RIA) measurements 
revealed increased serum PACAP levels during the third trimester and several 
changes in placental PACAP content in obstetrical pathological conditions, further 
supporting the function of PACAP during pregnancy.
Both the peptide and its receptors have been shown in different parts of the 
 placenta and the umbilical cord. PACAP influences blood vessel and smooth muscle 
contractility of the uteroplacental unit and is involved in regulation of local hor-
mone secretion. The effects of PACAP on trophoblast cells have been mainly stud-
ied in vitro. Effects of PACAP on cell survival, angiogenesis and invasion/
proliferation have been described in different trophoblast cell lines. PACAP 
increases proliferation and decreases invasion in proliferative extravillous 
 trophoblast cells, but not in primary trophoblast cells, where PACAP decreased the 
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secretion of various angiogenic markers. PACAP pretreatment enhances survival of 
non-tumorous primary trophoblast cells exposed to oxidative stress, but it does not 
influence the cell death-inducing effects of methotrexate in proliferative extravil-
lous cytotrophoblast cells. Interestingly, PACAP has pro-apoptotic effect in chorio-
carcinoma cells suggesting that the effect of PACAP depends on the type of 
trophoblast cells. These data strongly support that PACAP plays a role in normal 
and pathological pregnancies and our review provides an overview of currently 
available experimental data worth to be further investigated to elucidate the exact 
role of this peptide in the placenta.
Keywords Pregnancy • Trophoblast • Proliferation • Migration • Placenta • Human
 Introduction
Pituitary adenylate cyclase activating polypeptide (PACAP) was first described as a 
hypothalamic neuropeptide acting on the pituitary [1]. Numerous subsequent stud-
ies have described its regulatory effects in the hypothalamo-hypophyseal-endocrine 
gland axis at all levels. Shortly after its discovery it became evident that PACAP 
occurs at high levels in several peripheral organs, especially in the gonads. Arimura 
and coworkers showed that after the hypothalamus, highest PACAP levels are found 
in the testis [2]. This drew the attention to the peptide as a regulator of male fertility 
and reproduction. Indeed, PACAP was found to influence spermatogenesis at vari-
ous levels [3–6].
PACAP is also involved in female reproductive functions. Although our knowl-
edge on PACAP in reproductive functions is still limited, currently available data 
clearly indicate that the neuropeptide plays an important regulatory role in female 
reproductive physiology and pathology (rev. [7]). Briefly, PACAP, at the hypotha-
lamic level, influences receptive behavior in female rodents, in association with 
gonadotropin releasing hormone and steroids [8], and plays an important modula-
tory role in pituitary hormone production. The role of PACAP in the hypothalamo- 
pituitary- gonadal axis has been reviewed several times previously [9–13] and is 
reviewed in the present book in two chapters (11. and 12.). PACAP is present in the 
ovary, in the ovarian follicular fluid and plays an important role in oocyte matura-
tion [7, 14, 15]. In humans, the level of immunoreactive PACAP in the follicular 
fluid of hyperstimulated women is correlated with the number of retrieved oocytes 
[16]. PACAP also plays a role in the muscle contraction of the vaginal wall as well 
as that of the uterus and uterine tube [17–19]. Decreased immunoreactivity was 
shown in vaginal wall diseases and the plasticity of the PACAPergic system was 
demonstrated after vaginal reconstructive surgery [20, 21]. The PACAPergic inner-
vation of the female genital tract was also described and has been associated with 
nerves originating from the paracervical ganglia [22, 23].
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During pregnancy, the serum level of PACAP increases in the third trimester in 
healthy pregnant women and it markedly decreases during delivery, reaching pre-
birth levels 3 days after delivery [24]. Winters and colleagues indicated a possible 
difference between cesarian and vaginal births regarding PACAP levels in the fetal 
cord blood [25]. In pregnant rats, Papka et al. [26] detected PACAP immunoreactiv-
ity in cervical nerves, lumbosacral dorsal root ganglia and in the spinal cord. 
Immunoreactivity showed changes during pregnancy, indicating that sensory nerve- 
derived PACAP is involved in the innervation of the cervix and may play a role in 
cervical ripening [26]. The role of PACAP in reproduction and offspring care does 
not seem to finish with birth: PACAP plays a complex regulatory role in breastfeed-
ing. The action of PACAP on prolactin synthesis and release is complex and influ-
enced by several factors [27, 28]. The high concentrations of PACAP in the milk 
suggest that the peptide plays a role in the development of the newborn [29–31]. 
Equally possible function of PACAP in the milk is a local regulatory action of milk 
production and/or mammary gland development [32, 33]. (This is reviewed else-
where in this book by Tamas and co-workers 49.). In addition, PACAP was impli-
cated to play a role in maternal behavior as showed by the decreased maternal 
crouching behavior of PACAP knockout mice [34].
It seems that placental functions of the neuropeptide are somewhat neglected in 
spite of the findings of Isaac and Sherwood [35], who described that the reproduc-
tive rate of PACAP knockout mice is lower due to implantation insufficiency, clearly 
indicating a placental role of endogenous PACAP. The present review briefly sum-
marizes the occurrence and actions of PACAP and its receptors in the placenta.
 Occurrence of PACAP and PACAP Receptors in the Placenta
Occurrence of PACAP and its receptors are summarized in a schematic drawing 
(Fig. 23.1). The gene encoding VPAC receptors was found to be weakly expressed 
in human placenta at relative prevalent levels comparable to that in the testis, kidney 
and thymus [36]. Another study also confirmed these findings [37].
Subsequent studies gave further insight into the occurrence and distribution of 
PACAP and its receptors in the placenta. Radioimmunoassay and immunocytochem-
istry first confirmed the expression of PACAP27 and PACAP38 in human placentas 
[38]. PACAP levels in the placenta were compared to those in the isthmic region of 
the uterus and in the umbilical cord. Both forms of PACAP could be detected in the 
examined specimens of the uteroplacental unit. PACAP38 concentration was higher 
than PACAP27 levels in all examined regions. Uterus and placenta showed similar 
levels of immunoreactivity, while intensity in the umbilical cord was much weaker 
[38]. These authors found no immunoreactive nerve fibers in the placenta or umbili-
cal cord, immunoreactive nerve fibers were only present in the uterus, with isthmic 
region and nonpregnant myometrium showing stronger immunoreactivity than preg-
nant uterus. PACAP immunoreactivity by radioimmunoassay was confirmed later by 
Brubel et al. [39]: both forms of the peptide could be detected with PACAP38 
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 showing stronger immunoreactivity, in agreement with the above earlier observa-
tions. Furthermore, it was also found that different parts of the human placenta con-
tained similar levels of PACAPs, such as central maternal, peripheral maternal, central 
fetal, and peripheral fetal parts. The umbilical cord showed very weak immunoreac-
tivity. In addition, Brubel et al. [39] also compared the level of immunoreactivity in 
the 1st trimester samples and full-term placentas. Markedly stronger immunoreactiv-
ity for PACAP38 was found in full-term placentas on both the maternal and fetal 
sides. In contrast, PACAP27-immunoreactivity only increased on the maternal side, 
while it did not change on the fetal side towards the end of pregnancy.
Scaldaferri and collagues [40] studied PACAP and PAC1 receptor expression by 
means of Northern blot analysis, polymerase chain reaction (PCR) and immunohis-
tochemistry. The authors detected the presence of PACAP and PAC1 receptor in 
both rat and full-term human placentas. In human placentas, strong immunohisto-
chemical staining was observed in stromal cells surrounding blood vessels and 
weaker signal was detected in vessel walls in stem villi. In terminal villi, stromal 
cells expressed PACAP38 immunoreactivity. In stem villi, the stromal immunoreac-
tivity was restricted to the periphery, while this spatial distribution pattern was lack-
ing in terminal villi, where immunostaining was dispersed throughout the stroma. In 
rat placentas, several immunostained cells were observed in the labyrinth and in the 
villous-like structures of the intraplacental yolk sac, structures derived from yolk 
sac extensions into placental disc during late pregnancy [40].
Isoforms of the PAC1 receptor were also studied by RT-PCR. Different isoform 
expression was revealed in rat and human placentas. Rat placenta was shown to 
express 3 isoforms: the short, hip or hop variant and the hip-hop variant. In contrast, 
human placenta only expressed the SV2 form, homologous to the rat hop form. 
Radioligand receptor binding assay revealed that the relative potencies of PACAP- 
related peptides were PACAP27, PACAP38 with comparable strong binding (almost 
equipotent, PACAP27 slightly stronger) and VIP with weaker binding (10 times less 
potent). Growth hormone releasing hormone and unrelated peptides, such as beta-
endorphin and corticotropin-releasing hormone, did not bind to the receptor [40].
Fig. 23.1 Distribution of PACAP and PACAP receptors in the human placenta. (A). Representative 
photomicrograph of the human placenta indicating the parts depicted in the (B) schematic illustra-
tion of the human placenta. Star: PACAP38 immunohistochemistry, filled circle: PACAP mRNA, 
filled triangle: PAC1 mRNA, filled square: PACAP38 radioimmunoassay, open square: PACAP27 
radioimmunoassay. Exact localization of VPAC receptor is not known
G. Horvath et al.
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PACAP and PAC1 receptor mRNAs were investigated in rat placenta also by 
Koh and coworkers [41]. Rat placenta consists of decidua basalis, junctional and 
labyrinth zones. Expression of PACAP and PAC1 receptor mRNA was detected by 
in situ hybridization in decidual cells, and in chorionic vessels and stromal cells of 
the labyrinth zone [41]. In decidual cells, signals were strongest on day 13.5 of 
gestation, then decreased with more advanced stages. No signal could be detected 
in the junctional zone. In contrast, signals were gradually increasing with advancing 
pregnancy in the labyrinth zone, in the branching villi, stem villi and also in chori-
onic vessels.
Koh et al. [42] investigated the expression of PACAP and PAC1 receptor mRNA 
from human legal abortions of 6–7 weeks, from induced abortions of 14–24 weeks 
(second trimester) and term placentas by cesarian section or normal vaginal deliv-
ery. In situ hybridization revealed expression of PACAP and PAC1 receptor mRNAs 
in stem villi and terminal villi. In 7- and 14-week-old samples, PACAP mRNA was 
detected in stroma cells surrounding blood vessels within stem villi, with moderate 
expression level, while stronger expression of PACAP mRNA was found at later 
stages [42]. PACAP mRNA was only weakly expressed in cytotrophoblast and syn-
cytiotrophoblast cells. PAC1 receptor expression was detected in the same areas: 
stronger expression was described in stroma cells of the villi, while weaker expres-
sion in the trophoblast cells. Similar pattern of VIP immunoreactivity was detected 
by Marzioni and coworkers [43]. Immunostaining was present in both trophoblast 
layers and in the endothelium of the fetal vessels.
The gradual increase of the mRNA expression for both PACAP and its specific 
receptor implies a role of PACAP in placental growth. The findings with RIA also 
confirmed these increasing levels in late placentas compared to early placentas [4].
 Expression of PACAP in Pathological Pregnancies
Butadiene diepoxide is a reactive metabolite of 1,3-butadiene that is an important 
industrial chemical and causes a dose-dependent inhibition of deciduoma develop-
ment in rats [44, 45]. Placental expression of PACAP mRNA significantly decreased 
in rats pretreated with 1,3-butadiene, a chemical toxin for reproduction in rats [44, 
46]. The decrease was more drastic on gestation day 12 (63 %) than on day 9 (48 %).
Our recent preliminary investigations have focused on the levels of PACAP38 
and PACAP27 in cases of different pathological situations. These measurements 
were done in order to show possible changes of PACAP expression caused by 
maternal smoking during pregnancy or fetal distress or hypoxia leading to presence 
of meconium in the amniotic fluid. Human placentas were collected from full-term 
placentas. Samples were taken from the chorionic villi (fetal side), the decidua 
(maternal side) and the umbilical cord. Four different groups were examined: (1) 
normal pregnancy and birth; (2) amniotic fluid with meconium—premature birth 
(36–38 weeks); (3) premature birth (31–32 weeks) with smoking during pregnancy; 
(4) post term birth with smoking during pregnancy (n = 3 in all groups).
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The procedure used was in accordance with protocols approved by the ethical 
committee (no. 2784,3117, University of Pecs; 8-28/92 009-10 I 8EKU, ETT 
TUKEB, Ministry of Health, Hungary). Tissue samples were weighed and homoge-
nized in ice-cold distilled water. The homogenate was centrifuged (12,000 rpm, 4 °C, 
30 min), and the supernatant was further processed for RIA analysis of PACAP38 
and PACAP27 contents, as previously described [47, 48].
Briefly, the conditions were as follows: antisera: PACAP38 “88111-3” (working 
dilution, 1:10,000) and PACAP27 “88123” (dilution: 1:45,000); tracer: mono- 125I- 
labelled ovine PACAP24-38 and mono-125I-labelled ovine PACAP27 prepared in 
our laboratory (5000 cpm/tube); standard: ovine PACAP38 and PACAP27 ranging 
from 0 to 1000 fmol/ml; buffer: assay prepared in 1 ml of 0.05 mol/l (pH 7.4) phos-
phate buffer containing 0.1 mol/l sodium chloride, 0.25 % (wt/vol) bovine serum 
albumin, and 0.05 % (wt/vol) sodium azide; incubation time: 48–72 h of incubation 
at 4 °C; separation solution: charcoal/dextran/milk powder (10:1:0.2 g in 100 ml of 
distilled water). Results are given as fmol/mg PACAP38-like immunoreactivity and 
PACAP27-like immunoreactivity in the tissue samples. Differences between 
PACAP contents were assessed by ANOVA test.
As sample sizes were low, no definite statistical comparison was possible, but 
some conclusions on tendencies can be drawn based on these preliminary results. We 
found detectable differences in levels of PACAP38 between pathological and physi-
ological pregnancies suggesting that PACAP expression may be disturbed or upregu-
lated during pathological events related to pregnancy (Fig. 23.2). PACAP27 levels 
did not show pronounced alterations in any examined condition. In accordance with 
previous results, levels of PACAP27 were significantly lower than PACAP38 levels 
in each sample. Under hypoxic condition, as indicated by the presence of meconium 
in the amniotic fluid, PACAP levels did not change in most samples. Only a slight 
decrease was observed in the chorionic villi and in the umbilical cord. Samples from 
premature births of smoking mothers showed marked increases in all regions exam-
ined except for the central decidua, where a slight decrease was observed. Decreases 
were also detected from samples derived from post term births of smoking mothers. 
Although our results are preliminary from limited number of clinical cases, some 
tendencies are promising as it seems that PACAP levels change in some pathological 
conditions. PACAP alterations have been observed in several diseases in both tissue 
samples and body fluids including plasma, cerebrospinal fluid and follicular fluid [16, 
49]. Recent studies have shown that PACAP levels were lower in lung cancer, colon 
and kidney tumor samples compared to healthy tissue, while higher in prostate cancer 
samples compared with samples from benign prostatic hyperplasia [50, 51]. As 
PACAP is indicated as a potential biomarker for various conditions by several stud-
ies, it would be important to conduct a clinical study including enough pathological 
placenta samples to draw final conclusions (clinical review: see Reglodi et al. in this 
book, chapter 2.).
G. Horvath et al.
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 Effects of PACAP in Vessels of the Placenta
Effects of PACAP on different components and cells of the placenta are summarized 
in Table 23.1. Steenstrup et al. [38] investigated the effects of PACAP on vessels and 
smooth muscle contractility in the uteroplacental unit. They found that preincubation 
of the vessels with PACAPs and VIP produced a significant and concentration- 
dependent inhibition of the norepinephrine-induced contraction on the intramyome-
trial and stem villus arteries. The high concentration needed for significant relaxation 
indicates that the local release of the peptides is necessary to achieve this effect 
in vivo. These results show that PACAP causes relaxation of the placental vessels. In 
contrast, no effect was observed on either the amplitude, tone or frequency of strips 
of spontaneously contracted myometrial smooth muscle obtained from pregnant 
women [38]. These observations indicate that PACAP may be involved in the regula-
tion of the uteroplacental blood flow. The time-related localization of endometrial/
Fig. 23.2 Levels of PACAP27 and PACAP38 in placentas from healthy and pathological pregnan-
cies. Results are given as mean fmol/mg tissue PACAP ± SEM. Differences between levels of 
PACAP38 and PACAP27-like immunoreactivities were significant in all cases
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Table 23.1 Summary of the effects of PACAP in the placenta
Cells/region of placenta Effect
PACAP 
concentration 
(M) Reference
Stem villous arteries Relaxation 10−10–10−6 [38]
Intramyometrial arteries Relaxation 10−10–10−6 [38]
JEG3 choriocarcinoma cells cAMP increase, IL-6 secretion, 
alpha-subunit gene transcription
10−7 [52]
JEG3 choriocarcinoma cells No influence on survival of cells 
exposed to oxidative stress
10−7 Horvath et al. 
unpublished 
observation
JAR choriocarcinoma cells Decreased survival in cells 
exposed to oxidative stress or 
hypoxia
10−7 [53]
JAR choriocarcinoma cells No influence on survival of cells 
exposed to LPS, ethanol, 
methotrexate
10−9–10−7 [39, 53]
JAR choriocarcinoma cells Phosphorylation of ERK1/2 and 
JNK↑; Akt, GSK-3β, and p38 
MAPK↓, Bax expression↓; in 
cells exposed to oxidative stress, 
PACAP decreased 
phosphorylation of all these
10−7 [53]
JAR choriocarcinoma cells Agonistic effects of PACAP6- 38 
on signaling
10−7 [62]
HTR-8/SVneo nontumorous 
primary trophoblast cells
Pretreatment increased survival 
in oxidative stress, co-treatment 
no effect
10−8–10−7 [61]
HTR-8/SVneo nontumorous 
primary trophoblast cells
No effect on invasion 10−7 [61]
HTR-8/SVneo nontumorous 
primary trophoblast cells
Reduced levels of angiogenic 
factors active A, ADAMTS-1, 
angiogenin, angiopoietin-1, 
endocrine gland-derived 
vascular endothelial growth 
factor, and endoglin
10−6 [61]
HIPEC65 proliferative 
extravillous cytotrophoblast 
cells
Induced proliferation, but no 
effect on methotrexate-induced 
cell death
decreased invasion
10−7 [61]
Decidual and peripheral 
mononuclear cells from 
early pregnancies
No effect on secreted 
angiogenic molecules or 
inflammatory cytokine 
production
10−6 [61]
G. Horvath et al.
t1.1
t1.2
t1.3
t1.4
t1.5
t1.6
t1.7
t1.8
t1.9
t1.10
t1.11
t1.12
t1.13
t1.14
t1.15
t1.16
t1.17
t1.18
t1.19
t1.20
t1.21
t1.22
t1.23
t1.24
t1.25
t1.26
t1.27
t1.28
t1.29
t1.30
t1.31
t1.32
t1.33
t1.34
t1.35
t1.36
t1.37
t1.38
t1.39
t1.40
t1.41
t1.42
t1.43
t1.44
397
uterine PACAP was described by Spencer et al. [45]. PACAP mRNA pattern showed 
similarity with that of the progesterone receptor during decidualization, but it was 
consistently lower during gestation. Furthermore, both uterine and placental mRNA 
expression pattern of decidual prolactin-related protein corresponded to PACAP and 
progesterone receptor mRNA levels. They suggest that PACAP could be important 
in facilitating endometrial blood flow and increase availability of metabolic sub-
strates to the developing deciduoma or embryo [45].
 Effects on Hormonal Secretion of the Placenta
Using JEG3 choriocarcinoma cells PACAP was found to induce a 12-fold increase 
in cAMP secretion [52]. This action of PACAP was rapid, cAMP increase started 
already after 30 min. cAMP in the placenta is known to stimulate alpha-subunit 
expression. Alpha-subunit of the hypophyseal hormones LH, FSH, and TSH is also 
present in the placental hormone human chorionic gonadotropin. PACAP38 was 
found to positively regulate alpha-gene transcription in JEG3 cells, with maximal 
effect at 100 nM concentration. The time course of this effect showed that PACAP 
effect started after 8 h. Similar effects were observed with the homolog peptide, 
VIP, but the effects of VIP an alpha-gene transcription started only after 24 h [52]. 
These findings show that PACAP may be involved in placental hormone secretion, 
and the similar effects of PACAP and VIP suggest that these effects are mediated by 
the shared VPAC receptors.
 Effects of PACAP on Survival of Trophoblast Cells
Effects of PACAP on trophoblast cell survival were studied in JAR human choriocar-
cinoma cells [53]. PACAP treatment alone did not influence the survival rate. Cells 
exposed to oxidative stress induced by H2O2 showed decreased survival rate, which 
was further decreased by PACAP. A similar effect was observed in cells undergoing 
chemically induced hypoxia by CoCl2. No effects on survival were observed in cells 
exposed to lipopolysaccharide (LPS), methotrexate or ethanol [39, 53]. These find-
ings were contradicting the general survival-promoting effect of PACAP observed in 
many different cell lines and tissues both in vitro and in vivo [54]. Examining the 
signaling pathway revealed that PACAP treatment alone slightly increased phosphor-
ylation of ERK1/2 (extracellular signal-regulated kinase) and JNK (c-Jun N-terminal 
kinase) but decreased that of Akt (protein kinase B), MAPK (mitogen-activated pro-
tein kinase), GSK-3β (glycogen synthase kinase 3 beta) and the expression of Bax. 
Oxidative stress alone increased phosphorylation of JNK and slightly decreased that 
of Akt, ERK, and GSK-3β, while no changes were observed in the expression of 
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phospho-p38 and Bax. In cells exposed to oxidative stress, PACAP treatment 
decreased phosphorylation of all of these examined signaling molecules compared to 
H2O2-treated controls. These results indicate that PACAP sensitizes the cells to some 
stressors, like oxidative stress and in vitro hypoxia, while it does not affect the delete-
rious effects of other stressors [53]. The reason for this is not known at the moment, 
and may or may not reflect the physiological role of the peptide, since these experi-
ments were performed in choriocarcinoma cells, in which the receptor expression 
and signaling induced by PACAP may be significantly altered.
Similar results were described in retinoblastoma cells, where PACAP treatment 
induced cell death [55] in spite of the well-known protective effects of PACAP in the 
retina [56, 57]. PACAP also inhibited the growth of the neuronal tumor medulloblastoma 
in spite of the well-known neuroprotective effects of the peptide [58–60]. An equally 
possible explanation is that the sensitizing effect of PACAP to stressors such as hypoxia 
and oxidative stress may be involved in the adaptation promoting effect of PACAP in 
pregnancy and under pathological conditions. The first explanation is supported by later 
findings in non-tumorous primary trophoblast cells (HTR-8/Svneo cells), where PACAP 
pretreatment led to a significant increase in survival measured by MTT test in cells 
exposed to oxidative stress by H2O2, while co-treatment had no effect [61]. However, 
PACAP treatment did not influence the cell death-inducing effect of methotrexate in 
HIPEC65 proliferative extravillous cytotrophoblast cell line, but induced proliferation of 
these cells when treated alone with PACAP [61]. These results show that the effects of 
PACAP on proliferation and survival of trophoblast cells depend on the type of stressor, 
the timing of treatment and the type of cell.
Another interesting finding regarding survival and signaling effects in this cell 
line was that the generally accepted PAC1/VPAC2 antagonist PACAP6-38 exerted 
agonistic effects in JAR cells [62]. This does not seem to be specific for this cell 
line, since agonistic effects were found for example on rat trachea neuropeptide 
release, retinoblastoma cell survival and cartilage and bone development [55, 62–
64]. The reason for this might be the expression of a yet unknown splice variant of 
the receptor or the tumorous nature of the JAR cells.
 Effects of PACAP on Invasion of Trophoblast Cells
PACAP treatment did not influence the invasion of HTR-8/Svneo human first tri-
mester extravillous primary trophoblast cells, while it decreased the invasion of 
HIPEC invasive, proliferative extravillous cytotrophoblast cells [61].
 Effects of PACAP on Trophoblast Angiogenesis
Effects of PACAP on angiogenic factors were investigated in HTR-8/Svneo cells 
using an angiogenesis array method. Levels of several angiogenic markers were 
markedly decreased in the cell culture supernatant after 24 h of PACAP treatment. 
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Secreted levels of active A, ADAMTS-1, angiogenin, angiopoietin-1, endocrine 
gland-derived vascular endothelial growth factor, and endoglin were reduced [61]. 
In human peripheral blood and decidual mononuclear cells obtained from healthy 
pregnant women undergoing elective termination of apparently normal pregnancies 
no effect on levels of secreted angiogenic molecules was found. Similarly, PACAP 
treatment had no effect on the inflammatory cytokine production of these cells [61].
 Observations in PACAP Knockout Mice, Effects 
on Implantation
It has been reported several times that the reproductive rate of PACAP and PAC1 
receptor knockout mice is lower than that of wild types [34, 65]. The reason for this 
is not elucidated yet, several mechanisms may be responsible for this effect. For 
example, PACAP is involved in spermatogenesis and sperm motility [4], in steroid 
hormone synthesis, in ovarian folliculogenesis, and in reproductive behavior [34, 
35]. The small litter can also be due to the premature intrauterine death and early 
postnatal death due to defects in breathing and temperature regulation [66, 67]. In 
addition to this multifactorial mechanism, it seems that placental defects are also 
partially responsible for the lower reproductive rate of PACAP knockout mice. Isaac 
and Sherwood [35] observed that while the puberty onset, estrous cycle and seminal 
plugs of PACAP knockout mice were normal, significantly fewer PACAP null 
females gave birth following mating than wild types. The authors found no defect in 
ovulation, ovarian histology or fertilization of released eggs, only 13 % had 
implanted embryos 6.5 days after mating compared to 81 % in wild types. Levels of 
prolactin and progesterone were significantly lower in PACAP knockout females. 
These observations suggest that impaired implantation is involved in the observed 
decreased fertility, the details of which need further clarification [35].
In summary, we give a brief review of data supporting a role of PACAP in normal 
and pathological pregnancies. The currently available experimental data are worth 
to be further investigated to elucidate the exact role in the placenta and evaluate the 
potential biomarker value of PACAP in reproductive pathology.
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